Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q3 EPS of ($0.08), $0.03 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.